Tandem Diabetes Care, Inc. TNDM
As ofNov 20, 2026, 2:12 PM EST
- YTD
- -20.31%
- 1 year
- -10.18%
5D -2.18 (-10.96%)
- Market cap
- 1.23B
- Revenue (ttm)
- 1.08B
- Profit margin
- -4.58%
- EPS (ttm)
- -0.70
- Shares out
- 69.79M
- Forward P/E
- 188.09
- YTD return
- -20.31%
- 1-year return
- -10.18%
- 50-day average
- 17.27
- 200-day average
- 18.80
- Volume
- 854.74K
- Avg volume
- 2.24M
- Open
- 17.73
- Previous close
- 16.80
- Day's range
- 17.41 – 17.80
- 52-week range
- 12.26 – 29.65
- Beta
- 1.59
- Analysts
- Buy
- Price target
- 27.10 (+54.7%)
- Earnings date
- Feb 18, 2027
Key statistics
- Enterprise value
- 1.48B
- Price / sales
- 1.09
- Price / book
- 8.67
- Revenue growth
- 13.80%
- Free cash flow
- -65.56M
- Total cash
- 443.08M
- Total debt
- 736.54M
- Return on equity
- -36.73%
- Short % of float
- 31.02%
Fundamental scorecard
7 of 25 checks passed on TNDM’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 18.00
- Target (mean)
- 27.10
- Target (high)
- 50.00
- Strong buy2
- Buy12
- Hold11
- Sell0
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate 0.10612.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | 0.08 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.24533 | -0.10 | +0.15 | +59.24% |
| Aug 6, 2026 | Jun 30, 2026 | -0.32074 | -0.31 | +0.01 | +3.35% |
| May 7, 2026 | Mar 31, 2026 | -0.46 | -0.30 | +0.16 | +34.78% |
| Feb 19, 2026 | Dec 31, 2025 | -0.05 | -0.01 | +0.04 | +80.00% |
| Nov 6, 2025 | Sep 30, 2025 | -0.31 | -0.31 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Nov 6, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 7, 2026 | Barclays | init | — | Equal-Weight |
| Sep 30, 2026 | Citigroup | main | Neutral | Neutral |
| Sep 24, 2026 | Truist Securities | main | Buy | Buy |
| Aug 21, 2026 | William Blair | init | — | Outperform |
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- tandemdiabetes.com
News
This Elevance Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26
Tandem: Wait Out The 2027 Transition Before Chasing The Turnaround
Tandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options
Tandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options
Tandem Mobi Now FDA Cleared as World's First and Only Tubeless AID System with up to Seven Days of Wear Barclays Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $20
Wells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25
Tandem Diabetes Care Q3 2026 Earnings Call Transcript Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.072B Est
Your note
Sign in to keep a note on TNDM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN DICK P | Retired | Conversion of Exercise of derivative security | May 20, 2026 | 50,903 |
| BLICKENSTAFF KIM D | Director | Sale | Nov 20, 2024 | 0 |
| CARPENTER RICK | Chief Technology Officer | Conversion of Exercise of derivative security | Nov 12, 2026 | 33,378 |
| GASSER ELIZABETH ANNE | Officer | Conversion of Exercise of derivative security | Nov 12, 2026 | 35,901 |
| HANSEN SHANNON MARIE | Officer | Conversion of Exercise of derivative security | Nov 12, 2026 | 35,064 |
| MORRISON SUSAN M | Officer | Conversion of Exercise of derivative security | Nov 12, 2026 | 54,806 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.87% | 11,774,548 | 197.81M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.53% | 3,860,256 | 64.85M | Sep 29, 2026 |
| First Light Asset Management, LLC | 4.66% | 3,251,835 | 54.63M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.36% | 3,043,551 | 51.13M | Sep 29, 2026 |
| GW&K Investment Management, LLC | 4.16% | 2,903,529 | 48.78M | Sep 29, 2026 |
| State Street Corporation | 4.14% | 2,888,913 | 48.53M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.93% | 4,140,278 | 69.56M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.13% | 2,186,918 | 36.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.58% | 1,803,947 | 30.31M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.25% | 1,570,019 | 26.38M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.29% | 901,467 | 15.14M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.13% | 788,509 | 13.25M | Jun 29, 2026 |
